Table of contents
December 2004 Vol 3 No 12
- News and Analysis
- Research Highlights
- Focus on: Kinases in cancer
- Reviews
- Perspective
- Careers and Recruitment
Also this month:
- Article series: Model organisms
In this issue
p983 | doi:10.1038/nrd1603
Editorial: Keeping an open mind
p985 | doi:10.1038/nrd1591
News and Analysis
News
Novel initiative seeks genetic causes of diabetes risk
p987 | doi:10.1038/nrd1594
News
Patent fights rumble in China
p988 | doi:10.1038/nrd1595
News
Public molecules: small, but perfectly formed
p988 | doi:10.1038/nrd1596
News in Brief
Patent watch
Amgen loses UK patent
p990 | doi:10.1038/nrd1589
Patent watch
Intrinsic evidence trumps dictionary definitions
p990 | doi:10.1038/nrd1592
Patent watch
Elan and Mayo resolve Alzheimer's model dispute
p990 | doi:10.1038/nrd1593
Patent primer
What to do with your granted patent
p991 | doi:10.1038/nrd1584
An Audience With
Claire M. Fraser
p992 | doi:10.1038/nrd1598
Article series: Model organisms
From the analyst's couch
Targeting protein kinases
p993 | doi:10.1038/nrd1600
Fresh from the Pipeline
Bevacizumab
p995 | doi:10.1038/nrd1601
Research Highlights
RNA interference: Silencing the sceptics
p997 | doi:10.1038/nrd1588
Neurodegenerative diseases: Body-building for small molecules
p998 | doi:10.1038/nrd1585
Kinases: Making gains on glioma
p999 | doi:10.1038/nrd1599
Antiviral drugs: Inside the envelope
p1000 | doi:10.1038/nrd1587
News in Brief
Kinases | Biotechnology | Lung diseases | Antithrombotic drugs
p1000 | doi:10.1038/nrd1590
Inflammation: Nicotine goes into septic shock
p1998 | doi:10.1038/nrd1586
Focus on: Kinases in cancer
Reviews
Strategies to overcome resistance to targeted protein kinase inhibitors
Henrik Daub, Katja Specht & Axel Ullrich
p1001 | doi:10.1038/nrd1579
Development of TGF-
signalling inhibitors for cancer therapy
Jonathan M. Yingling, Kerry L. Blanchard & J. Scott Sawyer
p1011 | doi:10.1038/nrd1580
Reviews
Strategies to overcome resistance to targeted protein kinase inhibitors
Henrik Daub, Katja Specht & Axel Ullrich
p1001 | doi:10.1038/nrd1579
Development of TGF- signalling inhibitors for cancer therapy
Jonathan M. Yingling, Kerry L. Blanchard & J. Scott Sawyer
p1011 | doi:10.1038/nrd1580
Cyclodextrin-based pharmaceutics: past, present and future
Mark E. Davis & Marcus E. Brewster
p1023 | doi:10.1038/nrd1576
Challenges in bringing the bench to bedside in drug development for sle
Joan T. Merrill, Doruk Erkan & Jill P. Buyon
p1036 | doi:10.1038/nrd1577
Making protein interactions druggable: targeting PDZ domains
Kumlesh K. Dev
p1047 | doi:10.1038/nrd1578
Perspective
Opinion
Pharmaceutical patent challenges — time for reassessment?
Gregory Glass
p1057 | doi:10.1038/nrd1581
Natureview: Reviews and comment from the nature publishing group
p1063 | doi:10.1038/nrd1602
